Atea Pharmaceuticals, Inc. (AVIR)

Atea Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	351.37	48.63
Revenue Growth (YoY)	-	-	-	622.49%	-
Cost of Revenue	83.37	70.61	62.39	167.21	38.02
Gross Profit	-83.37	-70.61	-62.39	184.16	10.61
Selling, General & Admin	48.85	49.92	48.71	45.79	21.64
Operating Expenses	48.85	49.92	48.71	45.79	21.64
Operating Income	-132.22	-120.53	-111.1	138.38	-11.03
Interest & Investment Income	25.49	29.22	11.15	0.21	0.08
EBT Excluding Unusual Items	-106.73	-91.31	-99.95	138.59	-10.95
Other Unusual Items	-60.73	-43.63	-19.55	-	-
Pretax Income	-167.46	-134.94	-119.5	138.59	-10.95
Income Tax Expense	0.93	1.02	-3.59	17.4	-
Net Income	-168.39	-135.96	-115.91	121.19	-10.95
Net Income to Common	-168.39	-135.96	-115.91	121.19	-10.95
Shares Outstanding (Basic)	84	83	83	83	22
Shares Outstanding (Diluted)	84	83	83	88	22
Shares Change (YoY)	1.05%	0.17%	-5.67%	308.70%	113.98%
EPS (Basic)	-2.00	-1.63	-1.39	1.46	-0.51
EPS (Diluted)	-2.00	-1.63	-1.39	1.37	-0.51
Free Cash Flow	-135.5	-85.4	-122.93	-87.01	296.71
Free Cash Flow Per Share	-1.61	-1.02	-1.48	-0.99	13.74
Gross Margin	-	-	-	52.41%	21.82%
Operating Margin	-	-	-	39.38%	-22.68%
Profit Margin	-	-	-	34.49%	-22.51%
Free Cash Flow Margin	-	-	-	-24.76%	610.10%
EBITDA	-131.8	-120.11	-110.84	138.41	-11.01
EBITDA Margin	-	-	-	39.39%	-22.64%
D&A For EBITDA	0.42	0.42	0.26	0.03	0.02
EBIT	-132.22	-120.53	-111.1	138.38	-11.03
EBIT Margin	-	-	-	39.38%	-22.68%
Effective Tax Rate	-	-	-	12.55%	-

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q